STOCK TITAN

Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. (TNXP) announced that Tonix Management will present and host investor meetings at NobleCon 19 and the December Virtual Investor Summit. The company is a biopharmaceutical company focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio includes CNS, rare disease, immunology, and infectious disease product candidates. The company's lead development CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia, with topline data expected in late December 2023. The company's rare disease development portfolio includes TNX-2900 for the treatment of Prader-Willi syndrome. Tonix's immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the completion of the clinical phase of the Phase 3 registration-quality, double-blind, placebo-controlled RESILIENT1 study of TNX-102 SL2 (cyclobenzaprine HCl sublingual tablets) 5.6 mg for fibromyalgia management. The study achieved statistical significance (p=0.010) and showed a favorable adverse-event (AE) related discontinuation rate of 4.8% compared to prior studies. TNX-102 SL is a non-opioid analgesic medication designed to improve sleep quality and other fibromyalgia symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced enrollment of the first participant in a Phase 2 study of TNX-1900 for improving bone health in children with autism spectrum disorder (ASD). The study aims to investigate the efficacy and safety of TNX-1900 as a novel therapeutic agent to increase bone density and improve bone structure and strength in children with ASD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced financial results for Q3 2023, expecting topline results for Phase 3 fibromyalgia study and Phase 2 chronic migraine study by year end, along with progress in obtaining external support for clinical trials and revenue from marketed acute migraine products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) will conduct a Phase 1 clinical trial with TNX-1800, their vaccine candidate for COVID-19. The trial is expected to start in the second half of 2024 and will assess safety and immunogenicity in approximately 60 healthy adult volunteers. NIAID will cover the full cost of the trial, while Tonix will supply the vaccine candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced topline results from the Phase 2 study of TNX-601 ER in patients with major depressive disorder. The study did not achieve statistical significance on the primary endpoint, and as a result, Tonix is discontinuing development of TNX-601 ER. The company expects topline data results in December 2023 for its Phase 2 study of TNX-1900 in chronic migraine and Phase 3 study of TNX-102 SL in fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.95%
Tags
Rhea-AI Summary
Tonix Pharmaceuticals announced data from two oral presentations at recent medical conferences on their drug TNX-1500, currently in Phase 1 development for the prevention of organ transplant rejection. The data showed promising results in preclinical studies using genetically engineered pig hearts in baboon transplants. Tonix is enrolling in a Phase 1 trial in healthy volunteers to support the development of TNX-1500 for the prevention of allograft rejection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
-
Rhea-AI Summary
Tonix Pharmaceuticals completes clinical phase of Phase 2 study for TNX-1900 as a potential treatment for chronic migraines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Tonix Pharmaceuticals recently reported positive results from a Phase 2 study evaluating TNX-102 SL as a treatment for fibromyalgia-type long COVID. The study showed an effect size of 0.5 in improving fatigue, as well as consistent activity trending to improvements in sleep quality, cognitive function, disability, and patient global impression of change. TNX-102 SL did not achieve the primary endpoint of improving long COVID pain intensity scores. Tonix intends to request an End-of-Phase 2 meeting with the FDA to discuss a potential Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
covid-19
Rhea-AI Summary
Tonix Pharmaceuticals presents preclinical data on its horsepox-based live virus vaccine platform at the World Vaccine Congress Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none

FAQ

What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?

The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.19 as of November 22, 2024.

What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?

The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 38.2M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.

Tonix Pharmaceuticals Holding Corp.

Nasdaq:TNXP

TNXP Rankings

TNXP Stock Data

38.16M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHATHAM